Education
About Us
Working with TipRanks
Follow Us
Nrx Pharmaceuticals, Inc. (NRXP)
:NRXP
Top Page
NRX Pharmaceuticals
(NASDAQ:NRXP)
48Neutral
Positive Factors
Market Potential
There is no medicine approved to treat patients with bipolar depression suffering suicidal ideation, presenting a large market potential.
Product Development
The company plans to file NDA (New Drug Application) with the FDA for NRX-100 and NRX-101 by year end 2024.
Negative Factors
Financial Performance
The company reported a net loss of $7.9 million or EPS of $(0.75), missing consensus estimates.
NRX Pharmaceuticals (NRXP) vs. S&P 500 (SPY)
Market Cap
$35.86M
Dividend YieldN/A
Average Volume (3M)302.93K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS Growth57.84%
CountryUS
Employees2
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.15
Shares Outstanding16,915,648
10 Day Avg. Volume179,113
30 Day Avg. Volume302,932
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.00Price Target Upside1402.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
NRX Pharmaceuticals Business Overview & Revenue Model
Company DescriptionBig Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm's care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
How the Company Makes MoneyNRX Pharmaceuticals makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue model includes licensing agreements, partnerships, and collaborations with other pharmaceutical companies and healthcare organizations. These partnerships often involve milestone payments and royalties based on the successful development and sales of their therapies. Additionally, NRX Pharmaceuticals may receive funding from government grants, research institutions, and private investors that support their drug development initiatives.
NRX Pharmaceuticals Financial Statement Overview
Summary
NRX Pharmaceuticals is facing severe financial challenges, with negative revenue growth, persistent losses, and a high debt-to-equity ratio indicating significant leverage. The financial outlook is precarious, with immediate restructuring or capital needed.Income Statement
NRX Pharmaceuticals has shown a challenging financial performance with negative revenue growth and persistent losses. The TTM data shows a net loss with a negative net profit margin, indicating ongoing profitability issues. The company has not demonstrated revenue generation in recent periods, which is critical for the biotechnology industry.10
Very Negative
Balance Sheet
The balance sheet reveals significant financial strain, highlighted by negative stockholders' equity, which suggests insolvency risk. The high debt-to-equity ratio signifies heavy leverage, increasing financial risk. The equity ratio is negative, reflecting a precarious financial position that could impact future operations.5
Very Negative
Cash Flow
Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover its operational needs. The operating cash flow to net income ratio is unfavorable, further emphasizing cash management issues. However, financing activities have provided some liquidity, albeit not sustainably.15
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 5.00K | -5.00K | -4.00K | -2.00K | -907.41K | 0.00 | EBIT |
| -20.48M | -27.59M | -44.40M | -115.80M | -51.39M | ― | EBITDA |
| -19.22M | -30.02M | -39.75M | -93.04M | -51.72M | -713.19K | Net Income Common Stockholders |
| -20.38M | -30.15M | -35.23M | -71.72M | -12.35M | 408.43K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 11.08K | 4.59M | 20.05M | 27.61M | 1.86M | 6.00 | Total Assets |
| 70.80M | 7.32M | 25.82M | 32.73M | 2.94M | 32.07M | Total Debt |
| 690.00K | 9.16M | 10.53M | 518.00K | 797.00K | 1.95M | Net Debt |
| 678.92K | 4.57M | -9.53M | -27.09M | -1.06M | 1.95M | Total Liabilities |
| 1.26M | 19.05M | 18.41M | 11.92M | 46.71M | 2.57M | Stockholders Equity |
| 69.54M | -11.73M | 7.41M | 20.81M | -43.77M | 29.50M |
| Cash Flow | Free Cash Flow | ||||
| -12.67M | -21.66M | -39.77M | -37.71M | -2.27M | ― | Operating Cash Flow |
| -12.37M | -21.66M | -39.76M | -37.70M | -2.27M | -792.73K | Investing Cash Flow |
| 1.00K | -3.00K | -10.00K | -7.00K | -2.00K | 40.25M | Financing Cash Flow |
| 4.47M | 6.20M | 32.21M | 63.46M | 3.25M | -39.46M |
NRX Pharmaceuticals Technical Analysis
Negative
2.13
Price Trends
2.94
Negative
2.12
Positive
2.19
Negative
Market Momentum
-0.21
Positive
39.86
Neutral
46.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXP, the sentiment is Negative. The current price of 2.13 is below the 20-day moving average (MA) of 2.37, below the 50-day MA of 2.94, and below the 200-day MA of 2.19, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 39.86 is Neutral, neither overbought nor oversold. The STOCH value of 46.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRXP.
NRX Pharmaceuticals Risk Analysis
NRX Pharmaceuticals disclosed 93 risk factors in its most recent earnings report. NRX Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NRX Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $92.73M | ― | -535.10% | ― | ― | 54.63% | |
54 Neutral | $808.19M | ― | -913.07% | ― | 31.76% | 24.85% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
48 Neutral | $35.86M | ― | 108.28% | ― | ― | 57.84% | |
46 Neutral | $249.73M | ― | -33.88% | ― | ― | -22.66% | |
41 Neutral | $62.62M | ― | 41.08% | ― | -0.55% | 49.85% | |
38 Underperform | $2.47M | ― | -141.73% | ― | -60.00% | 68.32% |
* Healthcare Sector Average
Performance Comparison
NRXP
NRX Pharmaceuticals
2.13
-2.50
-54.00%
SLS
SELLAS Life Sciences Group
1.18
-0.31
-20.81%
TCRT
Alaunos Therapeutics
1.50
-14.80
-90.80%
KPTI
Karyopharm Therapeutics
7.53
-13.77
-64.65%
EOLS
Evolus
13.42
-0.62
-4.42%
AVIR
Atea Pharmaceuticals
3.10
-0.89
-22.31%
NRX Pharmaceuticals Earnings Call Summary
Earnings Call Date: Nov 14, 2024 | % Change Since: 83.62% | Next Earnings Date: Mar 17, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in reducing operating losses, advancing drug development, and strategic acquisitions. However, challenges remain in cash reserves, acquisition strategies, and revenue recognition policies. The company's outlook is optimistic with planned new drug applications and potential profitability by 2025.Highlights
Significant Reduction in Operating Loss
NRx Pharmaceuticals achieved a 74% reduction in net operating losses compared to the third quarter of 2023, forecasting profitability in 2025.
Progress in Drug Development
NRx advanced its life-saving products, NRX-100 and NRX-101, for new drug application filings in 2024, with potential FDA approvals expected in 2025.
Successful Acquisition Strategies
Hope Therapeutics signed nonbinding letters of intent to acquire two revenue-generating interventional psychiatry groups, with nondilutive acquisition financing close to finalization.
New CFO Appointment
Michael Abrams, with extensive financial and industry experience, appointed as the new Chief Financial Officer.
Reduction in R&D and G&A Expenses
Research and development expenses decreased by 52% year-over-year, while general and administrative expenses decreased by 11%.
Funding and Debt Management
Closed second tranche of funding, bringing total to $10.8 million, retired prior expensive debt, and settled litigation with Streeterville Capital.
Lowlights
Limited Cash Reserves
As of September 30, 2024, the company had only $1.6 million in cash and cash equivalents.
Challenges in Psychiatry Clinic Acquisitions
Limited number of clinics meet the desired model for precision psychiatry, requiring enhancement or building from the ground up.
Uncertain Revenue Recognition
Revenue recognition policies for upcoming acquisitions and services need to be finalized with auditors to ensure compliance.
Company Guidance
During the NRx Pharmaceuticals Third Quarter 2024 Earnings Call, the company provided several key metrics and guidance for the upcoming periods. NRx Pharmaceuticals achieved a 74% reduction in net operating losses compared to the third quarter of 2023, forecasting profitability in 2025 with anticipated revenue and EBITDA contributions from their subsidiary, Hope Therapeutics, alongside expected drug sales. The company secured $10.8 million in funding from an institutional investor, helping to retire expensive debt. The revenue target for Hope Therapeutics is set at $25 million by the end of 2024 and over $100 million by the end of 2025. Additionally, NRx plans to file NDAs for NRX-100 and NRX-101, with anticipated PDUFA dates in 2025.NRX Pharmaceuticals Corporate Events
Delistings and Listing ChangesExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
NRX Pharmaceuticals Board Changes and Nasdaq Compliance
Positive
Jan 22, 2025
On January 15, 2025, NRx Pharmaceuticals appointed Mike Taylor to its Board of Directors following Janet Rehnquist’s resignation. Taylor’s appointment aligns with a term sheet agreement involving JGS Holdings LLC, which includes a $25 million investment in HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, and the purchase of NRx Pharmaceuticals’ common stock. Additionally, on January 21, 2025, NRx Pharmaceuticals announced that it regained compliance with Nasdaq’s minimum market value requirement, ensuring continued listing on the Nasdaq Capital Market. This development marks a significant milestone for the company, enhancing its market position and providing stability for stakeholders.
Executive/Board Changes
NRX Pharmaceuticals Announces Board Resignation and New Nominee
Neutral
Jan 14, 2025
On January 7, 2025, Janet Rehnquist resigned from the Board of Directors of NRx Pharmaceuticals, effective immediately, without any disagreements with the company’s operations, policies, or practices. Her resignation follows the approval of a term sheet with JGS Holdings LLC, granting Sauer Nunes the right to nominate a new board member, with management currently reviewing nominees.
Executive/Board ChangesBusiness Operations and Strategy
NRX Pharmaceuticals Strengthens Leadership with New CFO Appointment
Positive
Nov 20, 2024
NRx Pharmaceuticals has appointed Michael Abrams as the new Chief Financial Officer, succeeding Richard Narido, who will focus on acquisition opportunities for HOPE Therapeutics. Abrams, an industry veteran with extensive experience in biotechnology and investment banking, aims to help NRx transition from a pre-revenue entity to a profitable biotechnology company. This move marks a significant step in NRx’s strategy to leverage Abrams’ expertise in financial operations and capital raising to strengthen its position in the market.
Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
NRX Pharmaceuticals Advances in Mental Health Sector
Positive
Nov 15, 2024
NRx Pharmaceuticals has reported significant progress in its third-quarter financials and business activities, focusing on its upcoming New Drug Applications for NRX-100 and NRX-101 aimed at treating suicidal depression and bipolar depression. The company has achieved a 74% reduction in net operating losses and anticipates first revenues by the end of 2024, with profitability expected in 2025. Key advancements include securing substantial funding, acquiring psychiatric clinics through its subsidiary HOPE Therapeutics, and preparing for clinical trials to support its drug applications, positioning itself to make a significant impact in the mental health sector.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.